Novavax (NVAX) Leases (2019 - 2024)
Historic Leases for Novavax (NVAX) over the last 6 years, with Q4 2024 value amounting to $139.7 million.
- Novavax's Leases fell 1279.01% to $139.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $139.7 million, marking a year-over-year decrease of 1279.01%. This contributed to the annual value of $139.7 million for FY2024, which is 1279.01% down from last year.
- Per Novavax's latest filing, its Leases stood at $139.7 million for Q4 2024, which was down 1279.01% from $160.2 million recorded in Q4 2023.
- Over the past 5 years, Novavax's Leases peaked at $160.2 million during Q4 2023, and registered a low of $7.8 million during Q4 2020.
- In the last 5 years, Novavax's Leases had a median value of $86.1 million in 2022 and averaged $87.3 million.
- Its Leases has fluctuated over the past 5 years, first surged by 41479.34% in 2021, then crashed by 1279.01% in 2024.
- Over the past 5 years, Novavax's Leases (Quarter) stood at $7.8 million in 2020, then surged by 414.79% to $40.1 million in 2021, then surged by 74.11% to $69.9 million in 2022, then surged by 129.37% to $160.2 million in 2023, then fell by 12.79% to $139.7 million in 2024.
- Its Leases was $139.7 million in Q4 2024, compared to $160.2 million in Q4 2023 and $69.9 million in Q4 2022.